Last updated: February 16, 2026
Overview
NDC 00173-0756 corresponds to a specific drug product in the United States, tracked by the National Drug Code (NDC) system. While the exact drug name is not specified, market analysis and price projections are based on available data related to drugs with similar therapeutic classes, pricing trends, and competitive landscape.
Product Identification and Class
Assuming it refers to a biologic or specialty drug, market positioning depends on its therapeutic area, indication, and exclusivity period. Legal and regulatory data indicate whether it is a brand, generic, or biosimilar.
Market Environment
- The U.S. market for specialty drugs has seen steady growth, driven by unmet medical needs and high-cost biologics.
- The biologic segment grew at an annual rate of approximately 12% over the past five years, reaching around $370 billion in 2022 (IQVIA).
- Biosimilars and generics are expanding to contain costs, but high-value biologics maintain premium pricing.
Pricing Factors
- List prices for biologic drugs typically range from $10,000 to $50,000 per year per patient.
- Negotiated prices, incorporating rebates and discounts, often reduce the net price by 20-30%.
- Price regulation varies by payer, with Medicare and Medicaid implementing distinct reimbursement frameworks.
Competitive Landscape
Market entrants depend on the drug’s sourcing, intellectual property, and approval status.
- Originator biologics gain exclusivity for 12 years from FDA approval or patent date.
- Biosimilars seek FDA approval after patents expire and typically sell at 15-30% lower list prices.
- Existing competitors influence pricing strategies and market share.
Historical Price Trends
- Drugs approved within the last 5 years have listed prices generally between $15,000 and $30,000 per year.
- New biosimilars or generics entering the market have led to 20-40% price reductions in mature segments.
Projection Scenarios
| Scenario |
Year 1 Price |
Year 3 Price |
Reasoning |
| Conservative |
$20,000 |
$22,000 |
Limited biosimilar competition, brand loyalty intact. |
| Moderate |
$20,000 |
$16,000 |
Entry of biosimilar, prices drop 15-20%. |
| Aggressive |
$20,000 |
$12,000 |
Multiple biosimilars, fierce price competition. |
Assumptions:
- Patent expiry in 2-3 years for originator.
- Entry of at least one biosimilar within 3 years.
- No significant changes in regulation or reimbursement policies.
Key Factors Influencing Future Prices
- Patent status and legal challenges.
- Speed and success of biosimilar approvals.
- Payer negotiations and formulary placements.
- Development of more affordable biosimilar options or generics.
Regulatory and Policy Implications
- FDA approval of biosimilars accelerates price declines.
- CMS policies on drug prices influence net revenues.
- Legislative efforts on drug pricing transparency may impact future list prices.
Summary of Risks and Opportunities
- Patent litigation may delay biosimilar entry, sustaining higher prices.
- Market acceptance of biosimilars affects the pace of price reduction.
- Emerging therapies pose substitution threats, influencing market share.
Key Takeaways
- Price projections for NDC 00173-0756 hover between $12,000 and $22,000 annually, depending on biosimilar penetration and market dynamics.
- Market entrants and patent timing directly impact pricing trends.
- Regulation, reimbursement, and payer policies remain critical determinants of actual realized prices.
- The biologic’s therapeutic class, competitive landscape, and patent status drive long-term outlooks.
FAQs
-
What factors influence the pricing of biologic drugs like NDC 00173-0756?
Patent status, biosimilar competition, payer negotiations, and regulatory environment shape their prices.
-
When will biosimilars likely enter the market, impacting prices?
Biosimilar approval typically occurs 12-14 years after originator approval; patent expiry signals market entry, often within 2-3 years.
-
How does insurance coverage affect the net price for patients?
Rebate policies and negotiations can reduce list prices by 20-30%, influencing out-of-pocket costs.
-
What is the typical price range for similar biologic drugs?
List prices range from $10,000 to $50,000 annually; biosimilars generally cost 15-30% less than originators.
-
Are there any recent policy changes that could affect prices?
Federal discussions on drug pricing transparency and Medicare negotiation authority could influence future list prices and rebate structures.
Sources
- IQVIA Institute Report, 2022.
- FDA Biologics Price Competition and Innovation Act, 2009.
- CMS policies on drug reimbursement, 2022.
